ストックスクリーナーアプリを入手
0.41
0.24%
-0.001
アフターアワーズ：
.41
前日終値:
$0.411
開ける：
$0.37
24時間の取引高:
150.17K
Relative Volume:
0.75
時価総額：
$9.46M
収益：
$81.89M
当期純損益:
$-55.20M
株価収益率:
-0.1521
EPS:
-2.6959
ネットキャッシュフロー:
$-67.40M
1週間 パフォーマンス:
+0.24%
1か月 パフォーマンス:
+6.30%
6か月 パフォーマンス:
-26.40%
1年 パフォーマンス:
-84.35%
1日の値動き範囲:
$0.37
$0.4199
1週間の範囲:
$0.37
$0.4199
52週間の値動き範囲:
$0.341
$3.8782
Turnstone Biologics Corp Stock (TSBX) Company Profile
名前
Turnstone Biologics Corp
セクター
電話
347-897-5988
住所
9310 ATHENA CIRCLE, SUITE 300, LA JOLLA
TSBX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TSBX
Turnstone Biologics Corp
|
0.41 | 9.46M | 81.89M | -55.20M | -67.40M | -2.6959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Turnstone Biologics Corp Stock (TSBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-05 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-11-15 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-10-14 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-08-16 | 開始されました | SVB Securities | Market Perform |
| 2023-08-15 | 開始されました | BofA Securities | Buy |
| 2023-08-15 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Turnstone Biologics Corp (TSBX) 最新ニュース
Turnstone Biologics Corp. SEC 10-K Report - TradingView
Turnstone Biologics Cuts Losses by $3.6M as Company Pivots Strategy - Stock Titan
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Significant Growth in Short Interest - Defense World
Turnstone Biologics (TSBX) Expected to Announce Earnings on Thursday - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.35 By Investing.com - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.35 - Investing.com India
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering, Business Wires News - AsiaOne
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Large Drop in Short Interest - Defense World
Turnstone Biologics Stock Hits 52-Week Low at $0.36 Amid Challenges - Investing.com Australia
Turnstone Biologics halts TIDAL-01 development, seeks alternatives - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 By Investing.com - Investing.com Canada
Cautious Hold on Turnstone Biologics Amid TIL Therapy Challenges and Strategic Alternatives - TipRanks
Analysts Offer Predictions for TSBX FY2024 Earnings - Defense World
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Leerink Partnrs Weighs in on TSBX FY2024 Earnings - Armenian Reporter
Turnstone Biologics (NASDAQ:TSBX) Stock Rating Lowered by Piper Sandler - Defense World
A Look at Turnstone Biologics Corp (TSBX) Shares in the Recent Past Indicates Growth - SETE News
TSBX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Turnstone Biologics to explore strategic alternatives - The Pharma Letter
Piper Sandler Downgrades Turnstone Biologics to Neutral From Overweight, Adjusts Price Target to $0.40 From $3.75 - Marketscreener.com
Turnstone Biologics Corp (NASDAQ: TSBX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel
Piper Sandler cuts Turnstone Biologics stock rating to neutral - MSN
Turnstone Biologics halts TIDAL-01 development, seeks alternatives By Investing.com - Investing.com South Africa
Ottawa-born Turnstone Biologics halting clinical studies, laying off staff - Ottawa Business Journal
TSBX’s price-to-book ratio: An indicator of the company’s performance - US Post News
Turnstone Biologics Stops Tidal-01 Trials, Explores Strategic Alternatives; Shares Rise - Marketscreener.com
Turnstone Biologics Halts TIDAL-01 Studies Amid Market Woes - TipRanks
Turnstone Biologics Announces Plans to Explore Strategic Alternatives - The Manila Times
Turnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives Review - Nasdaq
Scailyte Announces Collaboration With Turnstone Biologics to Identify Biomarker Signatures in Solid Tumors With TIL Therapy - ACCESS Newswire
Head to Head Survey: Turnstone Biologics (NASDAQ:TSBX) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Reviewing AlloVir (NASDAQ:ALVR) and Turnstone Biologics (NASDAQ:TSBX) - Defense World
Turnstone Biologics (NASDAQ:TSBX) Stock Price Down 9.1% – Time to Sell? - Defense World
Fmr LLC Boosts Stock Position in Turnstone Biologics Corp. (NASDAQ:TSBX) - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.44 By Investing.com - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.44 - Investing.com
Turnstone Biologics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Turnstone Biologics stock downgraded amid concerns over therapy scalability and funding - Investing.com
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Turnstone Biologics Faces Financial and Operational Challenges - TipRanks
Turnstone Biologics Reports 25% Response Rate in Cancer Trial, Extends Cash Runway to 2026 | TSBX Stock News - StockTitan
Turnstone advances TIL therapy for solid tumors at SITC meeting By Investing.com - Investing.com Australia
Turnstone advances TIL therapy for solid tumors at SITC meeting - Investing.com
Turnstone Biologics Corp (TSBX) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):